Citation

Cada DJ, Levien TL, Baker DE. Hosp. Pharm. 2011; 46(7): 519-526.

Copyright

(Copyright © 2011, Thomas Land Publishers)

DOI

10.1310/hpj4607-519

PMID

unavailable

Abstract

[Abstract unavailable]

Language: en

Keywords

human; suicide; insomnia; depression; anxiety; cause of death; risk assessment; treatment outcome; review; migraine; Asian; sex ratio; influenza; Hispanic; drug safety; placebo; food and drug administration; rheumatoid arthritis; drug efficacy; diarrhea; nausea; disease exacerbation; fever; cardiovascular disease; drug distribution; bronchitis; rash; systemic lupus erythematosus; side effect; infection; drug activity; arthralgia; myalgia; pharyngitis; drug half life; American Indian; skin manifestation; drug approval; drug contraindication; drug elimination; drug formulation; drug indication; drug clearance; thorax pain; drug hypersensitivity; mouth ulcer; hair loss; urinary tract infection; single drug dose; drug induced headache; pallor; respiratory tract infection; sinusitis; receptor blocking; discoid lupus erythematosus; lupus like syndrome; rhinopharyngitis; recommended drug dose; joint swelling; Sjoegren syndrome; limb pain; infusion; B cell activating factor; belimumab; flow rate; leg swelling; skin lupus erythematosus; Waldenstroem macroglobulinemia